An FDA panel voted 10-2 today that the investigational diabetes drug saxagliptin (Onglyza) does not put type 2 diabetes patients at an increased risk for cardiovascular events, but wants drugmaker Bristol-Myers Squibb to conduct long-term postmarketing studies to test the drug in older and sicker patients.
The two No votes on the panel came from John Teerlink, M.D., a cardiologist and director of the Heart Failure Clinic at the San Francisco Veterans Medical Center, and Kathleen Wyne, M.D., Ph.D., an endocrinologist at the Methodist Hospital Research Institute in Houston.
More
1 comment:
You forgot to mention that you predicted the opposite. Confess ! And you should confess in bold type!
Post a Comment